Glycoside derivatives and uses thereof

Abstract

This invention relates to compounds represented by formula (I): wherein the variables are defined as herein above, which are useful for treating diseases and conditions mediated by the sodium D-glucose co-transporter (SGLT), e.g. diabetes. The invention also provides methods of treating such diseases and conditions, and compositions etc. for their treatment.

We claim: 
     
         1 . A crystalline form of L-proline co-crystal of (2S,3R,4R,5S,6R)-2-[4-Chloro-3-(3,4-dihydro-2H-benzo[1,4]oxazin-6-ylmethyl)-phenyl]-6-hydroxymethyl-tetrahydro-pyran-3,4,5-triol. 
     
     
         2 . The crystal according to  claim 1 , wherein the molar ratio of L-proline to (2S,3R,4R,5S,6R)-2-[4-Chloro-3-(3,4-dihydro-2H-benzo[1,4]oxazin-6-ylmethyl)-phenyl]-6-hydroxymethyl-tetrahydro-pyran-3,4,5-triol is about 1:1. 
     
     
         3 . The crystalline form according to  claim 1 , wherein the crystalline form has a differential scanning calorimetry endotherm at about 64° C., about 104° C. and/or about 157° C. 
     
     
         4 . A crystalline form of L-proline co-crystal of (2S,3R,4R,5S,6R)-2-[4-Cyclopropyl-3-(2,3-dihydro-benzo[1,4]dioxin-6-ylmethyl)-phenyl]-6-hydroxymethyl-tetrahydro-pyran-3,4,5-triol. 
     
     
         5 . The crystal according to  claim 4 , wherein the molar ratio of L-proline to (2S,3R,4R,5S,6R)-2-[4-Cyclopropyl-3-(2,3-dihydro-benzo[1,4]dioxin-6-ylmethyl)-phenyl]-6-hydroxymethyl-tetrahydro-pyran-3,4,5-triol is about 1:1. 
     
     
         6 . The crystalline form according to  claim 4 , wherein the crystalline form has a differential scanning calorimetry endotherm at about 151° C. 
     
     
         7 . A crystalline form of L-proline co-crystal of (2S,3R,4R,5S,6R)-2-[3-(2,3-Dihydro-benzo[1,4]dioxin-6-ylmethyl)-4-ethyl-phenyl]-6-hydroxymethyl-tetrahydro-pyran-3,4,5-triol. 
     
     
         8 . The crystal according to  claim 7 , wherein the molar ratio of L-proline to (2S,3R,4R,5S,6R)-2-[3-(2,3-Dihydro-benzo[1,4]dioxin-6-ylmethyl)-4-ethyl-phenyl]-6-hydroxymethyl-tetrahydro-pyran-3,4,5-triol is about 1:1. 
     
     
         9 . The crystalline form according to  claim 7 , wherein the crystalline form has a differential scanning calorimetry endotherm at about 136° C. 
     
     
         10 . The crystal according to  claim 7 , wherein the molar ratio of L-proline to (2S,3R,4R,5S,6R)-2-[3-(2,3-Dihydro-benzo[1,4]dioxin-6-ylmethyl)-4-ethyl-phenyl]-6-hydroxymethyl-tetrahydro-pyran-3,4,5-triol is about 2:1. 
     
     
         11 . The crystal according to  claim 10 , wherein the crystalline form has a differential scanning calorimetry endotherm at about 176° C. 
     
     
         12 . The crystalline form according to  claim 10  having a powder X-ray diffraction pattern which is substantially the same as the powder X-ray diffraction pattern shown in  FIG. 4 .